RU2014134909A - ASAGETEROCYCLIC COMPOUNDS - Google Patents
ASAGETEROCYCLIC COMPOUNDS Download PDFInfo
- Publication number
- RU2014134909A RU2014134909A RU2014134909A RU2014134909A RU2014134909A RU 2014134909 A RU2014134909 A RU 2014134909A RU 2014134909 A RU2014134909 A RU 2014134909A RU 2014134909 A RU2014134909 A RU 2014134909A RU 2014134909 A RU2014134909 A RU 2014134909A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- pyrazin
- amino
- ethyl
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
1. Соединение формулы (I)или его стереоизомеры или таутомеры, или фармацевтически приемлемые соли каждого из вышеуказанных, включая их смеси во всех соотношениях, где2. Соединение по п. 1 или его стереоизомеры или таутомеры, или фармацевтически приемлемые соли каждого из вышеуказанных, включая их смеси во всех соотношениях, в котором остатки, не обозначенные более подробно, имеют значения, указанные для формулы (I), но в которомв Подформуле 1в Подформуле 2в Подформуле 3в Подформуле 4в Подформуле 5в Подформуле 6в Подформуле 7в Подформуле 8в Подформуле 9в Подформуле 10в Подформуле 11в Подформуле 12в Подформуле 13в Подформуле 14в Подформуле 15в Подформуле 16в Подформуле 17в Подформуле 18в Подформуле 19в Подформуле 20в Подформуле 21в Подформуле 223. Соединение по п. 1, где соединение выбирают из группы, включающей:1-(2-{6-[4-(5-Метил-пиридин-2-ил)-фенокси]-пиразин-2-иламино}-этил)-пиперидин-2-он,1-[2-(Метил-{6-[4-(5-метил-пиридин-2-ил)-фенокси]-пиразин-2-ил}-амино)-этил]-пиперидин-2-он,[6-(4-{5-[4-(6-{[2-(Ацетил-метил-амино)-этил]-метил-амино}-пиразин-2-илокси)-фенил]-пиридин-2-ил}-пиперазин-1-ил)-6-оксо-гексил]-амид 5-(2-оксо-гексагидро-тиено[3,4-d]имидазол-6-ил)-пентановой кислоты,{5-[4-(6-{[2-(Ацетил-метил-амино)-этил]-метил-амино}-пиразин-2-илокси)-фенил]-пиридин-2-илметил}-метил-амид 6-[5-(2-оксо-гексагидро-тиено[3,4-d]имидазол-6-ил)-пентаноиламино]-гексановой кислоты,N-[2-({6-[2-Фтор-4-(5-фтор-пиридин-2-ил)-фенокси]-пиразин-2-ил}-метил-амино)-этил]-N-метил-ацетамид,N-[2-({6-[2-Фтор-4-(5-метил-пиридин-2-ил)-фенокси]-пиразин-2-ил}-метил-амино)-этил]-N-метил-ацетамид,N-[2-({6-[2-Фтор-4-(6-морфолин-4-ил-пиридин-3-ил)-фенокси]-пиразин-2-ил}-метил-амино)-этил]-N-метил-ацетамид,N-[2-({6-[4-(2-Амино-пиримидин-4-ил)-фенокси]-пиразин-2-ил}-метил-амино)-этил]-N-метил-ацетамид,N-[2-({б-[4-(2-Циано-пиридин-4-ил)-фенокси]-пиразин-2-ил}-метил-амино)-этил]-N-метил-ацетамид,N-[2-({6-[4-(2-Фтор-пиридин-4-ил)-фенокси]-пиразин-2-и1. The compound of formula (I) or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the above, including mixtures thereof in all ratios, where2. The compound according to claim 1 or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the above, including mixtures thereof in all ratios, in which residues not indicated in more detail, have the meanings specified for formula (I), but in which in Formula 1c Sub-formula 2 in Sub-formula 3 in Sub-formula 4 in Sub-formula 5 in Sub-formula 6 in Sub-formula 7 in Sub-formula 8 in Sub-formula 9 in Sub-formula 10 in Sub-formula 11 in Sub-formula 12 in Sub-formula 13 in Sub-formula 14 in Sub-formula 15 in Sub-formula 16 in Sub-formula 17 in Sub-formula 18 in Sub-formula 19 in Sub-formula 20-in-Sub Rule 21 in Subformula 223. The compound of claim 1, wherein the compound is selected from the group consisting of: 1- (2- {6- [4- (5-Methyl-pyridin-2-yl) -phenoxy] -pyrazin-2-ylamino } -ethyl) -piperidin-2-one, 1- [2- (Methyl- {6- [4- (5-methyl-pyridin-2-yl) phenoxy] pyrazin-2-yl} amino) - ethyl] -piperidin-2-one, [6- (4- {5- [4- (6 - {[2- (Acetyl-methyl-amino) -ethyl] -methyl-amino} -pyrazin-2-yloxy) -phenyl] -pyridin-2-yl} -piperazin-1-yl) -6-oxo-hexyl] -amide 5- (2-oxo-hexahydro-thieno [3,4-d] imidazol-6-yl) - pentanoic acid, {5- [4- (6 - {[2- (Acetyl-methyl-amino) -ethyl] -methyl-amino} -pyrazin-2-yloxy) -phenyl] -pyridin-2-ylmethyl} -methyl amide 6- [5- (2-oxo-hexahydro-thieno [3, 4-d] imidazol-6-yl) -pentanoylamino] hexanoic acid, N- [2 - ({6- [2-Fluoro-4- (5-fluoro-pyridin-2-yl) phenoxy] pyrazin- 2-yl} -methyl-amino) -ethyl] -N-methyl-acetamide, N- [2 - ({6- [2-Fluoro-4- (5-methyl-pyridin-2-yl) -phenoxy] - pyrazin-2-yl} -methyl-amino) -ethyl] -N-methyl-acetamide, N- [2 - ({6- [2-Fluoro-4- (6-morpholin-4-yl-pyridin-3- yl) -phenoxy] -pyrazin-2-yl} -methyl-amino) -ethyl] -N-methyl-acetamide, N- [2 - ({6- [4- (2-amino-pyrimidin-4-yl) -phenoxy] -pyrazin-2-yl} -methyl-amino) -ethyl] -N-methyl-acetamide, N- [2 - ({b- [4- (2-Cyano-pyridin-4-yl) -phenoxy ] -pyrazin-2-yl} -methyl-amino) -ethyl] -N-methyl-acetamide, N- [2 - ({6- [4- (2-Fluoro-pyridin-4-yl) -phenoxy] - pyrazin-2-i
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12000559.0 | 2012-01-28 | ||
EP12000559 | 2012-01-28 | ||
PCT/EP2013/000050 WO2013110433A1 (en) | 2012-01-28 | 2013-01-10 | Azaheterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014134909A true RU2014134909A (en) | 2016-03-20 |
Family
ID=47603585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014134909A RU2014134909A (en) | 2012-01-28 | 2013-01-10 | ASAGETEROCYCLIC COMPOUNDS |
Country Status (15)
Country | Link |
---|---|
US (1) | US9493444B2 (en) |
EP (1) | EP2807154B1 (en) |
JP (1) | JP2015505542A (en) |
KR (1) | KR20140117641A (en) |
CN (1) | CN104080773B (en) |
AU (1) | AU2013212175B2 (en) |
BR (1) | BR112014018341A8 (en) |
CA (1) | CA2862698A1 (en) |
HK (1) | HK1202543A1 (en) |
IL (1) | IL233705A0 (en) |
MX (1) | MX2014009133A (en) |
RU (1) | RU2014134909A (en) |
SG (1) | SG11201404217XA (en) |
WO (1) | WO2013110433A1 (en) |
ZA (1) | ZA201406322B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
LT3417851T (en) | 2013-09-09 | 2020-11-25 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
CN105722835B (en) | 2013-09-11 | 2018-07-31 | 癌症研究协会:皇家癌症医院 | 3- aryl -5- substitution-isoquinoline-1-ketone compound and their therapy application |
JP6694811B2 (en) * | 2013-10-04 | 2020-05-20 | ノバルティス アーゲー | 3'end cap for RNAi agents for use in RNA interference |
ES2737148T3 (en) | 2013-12-16 | 2020-01-10 | Peloton Therapeutics Inc | Cyclic sulfone and sulfoximin analogs and uses thereof |
GB201322333D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | WNT pathway modulators |
EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
US10450300B2 (en) | 2015-10-08 | 2019-10-22 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
WO2017062688A1 (en) | 2015-10-08 | 2017-04-13 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
EP3651747A4 (en) | 2017-11-17 | 2020-07-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
WO2020252229A2 (en) * | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009155001A2 (en) * | 2008-05-27 | 2009-12-23 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
-
2013
- 2013-01-10 AU AU2013212175A patent/AU2013212175B2/en not_active Expired - Fee Related
- 2013-01-10 SG SG11201404217XA patent/SG11201404217XA/en unknown
- 2013-01-10 BR BR112014018341A patent/BR112014018341A8/en not_active IP Right Cessation
- 2013-01-10 KR KR1020147023947A patent/KR20140117641A/en not_active Application Discontinuation
- 2013-01-10 EP EP13701200.1A patent/EP2807154B1/en not_active Not-in-force
- 2013-01-10 RU RU2014134909A patent/RU2014134909A/en unknown
- 2013-01-10 JP JP2014553655A patent/JP2015505542A/en not_active Ceased
- 2013-01-10 CA CA2862698A patent/CA2862698A1/en not_active Abandoned
- 2013-01-10 MX MX2014009133A patent/MX2014009133A/en unknown
- 2013-01-10 WO PCT/EP2013/000050 patent/WO2013110433A1/en active Application Filing
- 2013-01-10 CN CN201380006903.4A patent/CN104080773B/en not_active Expired - Fee Related
- 2013-01-10 US US14/375,072 patent/US9493444B2/en not_active Expired - Fee Related
-
2014
- 2014-07-17 IL IL233705A patent/IL233705A0/en unknown
- 2014-08-27 ZA ZA2014/06322A patent/ZA201406322B/en unknown
-
2015
- 2015-03-27 HK HK15103108.6A patent/HK1202543A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2807154B1 (en) | 2015-12-23 |
SG11201404217XA (en) | 2014-08-28 |
BR112014018341A8 (en) | 2017-07-11 |
AU2013212175A1 (en) | 2014-09-11 |
AU2013212175B2 (en) | 2017-03-02 |
JP2015505542A (en) | 2015-02-23 |
IL233705A0 (en) | 2014-09-30 |
MX2014009133A (en) | 2014-10-13 |
KR20140117641A (en) | 2014-10-07 |
EP2807154A1 (en) | 2014-12-03 |
CN104080773B (en) | 2016-12-28 |
BR112014018341A2 (en) | 2017-06-20 |
CN104080773A (en) | 2014-10-01 |
HK1202543A1 (en) | 2015-10-02 |
ZA201406322B (en) | 2016-10-26 |
US20150005294A1 (en) | 2015-01-01 |
WO2013110433A1 (en) | 2013-08-01 |
CA2862698A1 (en) | 2013-08-01 |
US9493444B2 (en) | 2016-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014134909A (en) | ASAGETEROCYCLIC COMPOUNDS | |
JP2015505542A5 (en) | ||
ES2684120T3 (en) | Combination of an IAP inhibitor and a taxane | |
US20200038513A1 (en) | Modulators of fak proteolysis and associated methods of use | |
JP5886411B2 (en) | New pyrimidine derivatives | |
US20160074409A1 (en) | Treatment of Skeletal-Related Disorders | |
HRP20171655T1 (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
RU2007147382A (en) | COMPOUNDS WHICH ARE RAF INHIBITORS AND WAYS OF THEIR APPLICATION | |
JP6695353B2 (en) | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | |
JP2008540674A5 (en) | ||
JP2018500342A (en) | Triazolopyrimidine compounds and uses thereof | |
JP2010500414A5 (en) | ||
JP2011520941A5 (en) | ||
RU2013143028A (en) | Thiazolylphenylbenzenesulfonamide derivatives as kinase inhibitors | |
MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
RU2017102319A (en) | Intermittent Introduction of MDM2 Inhibitor | |
RU2017118165A (en) | Homolog Enhancer 2 Zestes Inhibitors | |
RU2017139246A (en) | CRYSTAL INHIBITOR FGFR4 AND ITS APPLICATION | |
CN103402519A (en) | Therapeutic agent for tumor | |
US20200361883A1 (en) | Sulfonamide Compounds and Use Thereof | |
RU2012147511A (en) | USE OF C-SRC INHIBITORS IN COMBINATION WITH PYRIMIDILAMINOBENZAMIDE FOR TREATMENT OF LEUKOSIS | |
JP2022500471A (en) | Quinuclidine-3-one compounds and their use in cancer treatment | |
HRP20100265T1 (en) | Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases | |
RU2015115360A (en) | NEW ANTI-INVASIVE COMPOUNDS | |
HRP20220571T1 (en) | Pyridylpyridone compounds |